The firm said it may use the loans to finance its $1.3 billion acquisition of Euroimmun Medical Laboratory Diagnostics.
The company also launched a clinical genomics service, offering newborn screening and high-throughput NSG for rare inherited diseases.
Euroimmun is a global leader in autoimmune testing and an emerging force in infectious disease and allergy testing, according to PerkinElmer.
PerkinElmer's subsidiary Wallac will now distribute the Amplidiag product line in Israel and in a number of countries in Africa.
The firm said revenues for its discovery and analytical solutions business rose 1 percent year over year while revenues from diagnostics rose 8 percent.
The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.
PerkinElmer may be nearing an FDA submission for a panel based on technology from the University of Washington, amid a push for state-mandated screening programs.
The company said the divestiture of its medical imaging business in the fourth quarter reduced revenues to below previous guidance.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
The agreement with PerkinElmer's Wallac Oy subsidiary will bring Mobidiag's real-time PCR-based gastrointestinal tests to a new market.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.